Interaction of sigma-1 receptor modulators with seizure development in pentylenetetrazole-induced kindled mice.
Adrenergic Uptake Inhibitors
/ toxicity
Animals
Convulsants
/ toxicity
Kindling, Neurologic
/ drug effects
Male
Mice
Mice, Inbred BALB C
Opipramol
/ toxicity
Pentylenetetrazole
/ toxicity
Piperazines
/ pharmacology
Random Allocation
Receptors, sigma
/ agonists
Seizures
/ chemically induced
Sigma-1 Receptor
Mice
Opipramol
Pentylenetetrazole
Seizure
Sigma-1 receptors
Journal
Epilepsy research
ISSN: 1872-6844
Titre abrégé: Epilepsy Res
Pays: Netherlands
ID NLM: 8703089
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
25
12
2018
revised:
08
04
2019
accepted:
01
05
2019
pubmed:
12
5
2019
medline:
14
7
2020
entrez:
12
5
2019
Statut:
ppublish
Résumé
This study aimed to investigate the effects of sigma receptor modulators, opipramol and BD-1063, on epileptogenesis in pentylenetetrazole (PTZ)-kindling model of epilepsy. Mice (n = 6/group) were received PTZ (30 mg/kg), PTZ plus opipramol (5 or 10 mg/kg), PTZ plus opipramol (5 mg/kg) plus BD-1063 (5 mg/kg, a selective sigma-1 receptor antagonist), and PTZ plus BD-1063 on alternate days for 15 days. Opipramol (5 and 10 mg/kg) + PTZ groups became fully kindled and had higher seizure scores compared to the PTZ group. In contrast, the PTZ plus BD-1063 and the PTZ plus opipramol (5 mg/kg) plus BD-1063 group did not show full kindling. These findings indicate that opipramol has a pro-convulsant effect, which is possibly mediated through activation of sigma-1 receptors.
Identifiants
pubmed: 31078073
pii: S0920-1211(18)30631-4
doi: 10.1016/j.eplepsyres.2019.05.001
pii:
doi:
Substances chimiques
1-(2-(3,4-dichlorophenyl)ethyl)-4-methylpiperazine
0
Adrenergic Uptake Inhibitors
0
Convulsants
0
Piperazines
0
Receptors, sigma
0
Opipramol
D23ZXO613C
Pentylenetetrazole
WM5Z385K7T
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
74-76Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.